KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Return on Sales (2016 - 2025)

Historic Return on Sales for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q3 2025 value amounting to 119.73%.

  • CRISPR Therapeutics AG's Return on Sales rose 230700.0% to 119.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.82%, marking a year-over-year decrease of 124900.0%. This contributed to the annual value of 10.93% for FY2024, which is 104400.0% down from last year.
  • As of Q3 2025, CRISPR Therapeutics AG's Return on Sales stood at 119.73%, which was up 230700.0% from 233.81% recorded in Q2 2025.
  • CRISPR Therapeutics AG's 5-year Return on Sales high stood at 0.84% for Q2 2021, and its period low was 18809.5% during Q4 2022.
  • Over the past 5 years, CRISPR Therapeutics AG's median Return on Sales value was 154.31% (recorded in 2021), while the average stood at 1239.08%.
  • In the last 5 years, CRISPR Therapeutics AG's Return on Sales plummeted by -187985500bps in 2022 and then soared by 188097900bps in 2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Return on Sales (Quarter) stood at 10.95% in 2021, then crashed by -171671bps to 18809.5% in 2022, then soared by 100bps to 0.29% in 2023, then crashed by -860bps to 2.21% in 2024, then tumbled by -5308bps to 119.73% in 2025.
  • Its last three reported values are 119.73% in Q3 2025, 233.81% for Q2 2025, and 157.22% during Q1 2025.